This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
JACC Specialty Journals
JACC: Basic to Translational Science - Effect of Crizanlizumab, a P-selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial
Released: Dec 27, 2021
Commentary by Dr. Douglas Mann
JACC: Basic to Translational Science - Effect of Crizanlizumab, a P-selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial
00:00:00
